Control Prenatal.pdf

•

0 likes•6 views

The document discusses various topics including percentages, arrows, and periods. It mentions multiple topics without providing details about any single one. The formatting includes arrows, percentages signs and other symbols but does not convey a clear purpose or meaning.

Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.

Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx

Dr. Rabia Inam Gandapore

Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya

Dr KHALID B.M

How to Give Better Lectures: Some Tips for Doctors

LanceCatedral

Antiulcer drugs Advance Pharmacology .pptx

Rohit chaurpagar

Anti ulcer drugs and their Advance pharmacology || Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining. ||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.

Non-respiratory Functions of the Lungs.pdf

MedicoseAcademics

These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract. Learning objectives: 1. Enlist the non-respiratory functions of the respiratory tract 2. Briefly explain how these functions are carried out 3. Discuss the significance of dead space 4. Differentiate between minute ventilation and alveolar ventilation 5. Describe the cough and sneeze reflexes Study Resources: 1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition 2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition 3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition 4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874

Recently uploaded

ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS

Dr. Vinay Pareek

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

bkling

Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx

Dr. Rabia Inam Gandapore

Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya

Dr KHALID B.M

How to Give Better Lectures: Some Tips for Doctors

LanceCatedral

Antiulcer drugs Advance Pharmacology .pptx

Rohit chaurpagar

Non-respiratory Functions of the Lungs.pdf

MedicoseAcademics

Ophthalmology Clinical Tests for OSCE exam

KafrELShiekh University

Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists

Saeid Safari

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...

Savita Shen $i11

For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls

Savita Shen $i11

ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx

Swetaba Besh

Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya

Dr KHALID B.M

The hemodynamic and autonomic determinants of elevated blood pressure in obes...

Catherine Liao

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

i3 Health

i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource. This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and Associate Division Director for Ambulatory Operations The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma. STATEMENT OF NEED Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL. Target Audience Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL). Learning Objectives 1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL 2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults 3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection

MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf

Jim Jacob Roy

24 Upakrama.pptx class ppt useful in all

DrSathishMS1

THOA 2.ppt Human Organ Transplantation Act

DrSathishMS1

BRACHYTHERAPY OVERVIEW AND APPLICATORS

Krishan Murari

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Oleg Kshivets

RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.